Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


OTCPK:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Shameless Investors
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(169)
•••
Comment by mstrmndon Jun 10, 2020 11:29pm
184 Views
Post# 31136900

RE:RE:RE:RE:RE:RE:Shameless Investors

RE:RE:RE:RE:RE:RE:Shameless Investors Even if you're telling the truth, sounds like you were gambling to lose...there's no need to gamble any more...the results are out...there's full visibility into the future of Antibe now

This is just part of the rollarcoaster ride - what's the next announcement?  More old news coming??    The next one has to be up.  What else did these guys do besides executing the clinical trial flawlessly??

Mole101 wrote: Lol... I sold a big chunk at .79 on the Friday before the news and bought more on the way down ( my choice and DD) ..please if you are as you pretend to be a shrouded investor, you should have seen this coming , instead you blabbing away  for a week and now crocodile tears... do as you please , Canada is a big country and sue as you please ...


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities